Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Disc Medicine, Inc. (IRON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $30.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $6.20M, a 63.16% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $1.20M, a 52.00% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $1.60M, a 6.67% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $5.50M, a 1000.00% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $30.20M, a 108.28% increase from fiscal 2024.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $14.50M, a 74.70% increase from fiscal 2023.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $8.30M, a 1283.33% increase from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $600.00K, a 100.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $30.20M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.40M derived: sum of 2 quarters · filed 2026-02-26 | $9.00M derived: sum of 3 quarters · filed 2026-02-26 | $14.50M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.80M derived: sum of 2 quarters · filed 2024-11-12 | $8.30M 10-Q · filed 2024-11-12 | $12.10M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.10M 10-Q · filed 2024-08-08 | $10.90M derived: sum of 3 quarters · filed 2026-02-26 | $13.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $5.50M 10-Q · filed 2024-05-09 | $9.30M derived: sum of 2 quarters · filed 2026-02-26 | $11.80M derived: sum of 3 quarters · filed 2026-02-26 | $13.30M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.30M derived: sum of 2 quarters · filed 2026-02-26 | $7.80M derived: sum of 3 quarters · filed 2026-02-26 | $8.30M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.00M derived: sum of 2 quarters · filed 2024-11-12 | $4.50M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.00M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $600.00K 10-K · filed 2024-03-21 | ||||
| 2021-12-31 | $300.00K 10-K · filed 2023-03-31 | $900.00K 10-K · filed 2022-03-10 | |||
| 2020-12-31 | $1.90M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |